Home' Australian Pharmacist : Australian Pharmacist August 2014 Contents Australian Pharmacist August 2014 I © Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
1. Pharmacist initiated health
promotion activities related to
asthma may include:
a) Undertaking spirometry, measuring full
blood counts and allergy testing.
b) Screening for lung cancer risk, measuring
full blood counts and allergy testing.
c) Screening for poor asthma control,
common comorbidities and modifiable
d) Screening for lung cancer risk and
e) None of the above.
2. In Australia a robust body of
evidence suggests that pharmacists’
clinical interventions for asthma can
improve patient outcomes such as:
a) Weight loss, total lung capacity,
lung age, lung structure integrity.
b) Asthma control, asthma related quality
of life and medication adherence.
c) Total lung capacity, lung elasticity and
d) Total lung capacity, sports fitness and
e) None of the above.
3. Clinical interventions for asthma in
the context of the 5CPA include:
a) Health education and counselling about
b) Counselling about medication
c) Suggesting regular review with a
d) Counselling about vitamin intake.
e) Referring patient for a preventer dose
change according to the step up/down
outlined in their action plan.
4. Conditions comorbid with asthma that
can affect asthma control include:
a) Allergic rhinitis, COPD, sleep apnea, reflux.
b) Vasomotor rhinitis, restless legs
syndrome, dyspepsia, depression.
c) Gluten intolerance, nasal obstruction,
parasomnias, peptic ulcer.
d) Insomnia, narcolepsy, nasal septal deviation
e) None of the above.
5. Current issues in asthma management
where pharmacists can play a part
a) Underdiagnoses and under-recognition
b) Under treatment of house dust mite allergy.
c) Under treatment of respiratory infections.
d) Overuse and underuse of preventers,
poor inhaler technique and modifiable
e) None of the above.
of administration (i.e. in the case of
asthma this may be the type of inhaler)
or medication-taking behaviour (e.g.
The Pharmaceutical Society
of Australia offers detailed guidance
to pharmacists on the eligibility,
requirements and practice standards for
pharmacists aiming to deliver these.
Health promotion and asthma
Health promotion is another key facet of
pharmacists’ roles in respiratory health.
The World Health Organization (WHO)
defines health promotion as ‘the process
of enabling people to increase control
over, and to improve, their health. It
moves beyond a focus on individual
behaviour towards a wide range of social
and environmental interventions’.
The Pharmaceutical Society of Australia’s
Self Care Program has an ACTION kit
for respiratory health entitled A breath
of fresh air. This is a community
pharmacy focussed step-by-step
guide for implementing a pharmacy
health promotion for people who have
respiratory conditions such as asthma
and/or COPD and may be a useful
resource (Available from the PSA website
for members at: www.psa.org.au/
selfcare/topic-based-action-kits). Table 2
highlights possible health promotion
strategies that would benefit Mrs M.
Chronic respiratory conditions such as
asthma can be well managed.
Optimal management requires a
concerted effort by the patient as well
as healthcare professionals.
Pharmacists can enact various roles
ranging from clinical interventions
to broader health promotional
Evidence from pragmatic
implementation trials suggests
that such interventions are feasible,
effective and stand to improve
outcomes for both the patient and the
health care system.
1. Global initiative for asthma (GINA). GINA report, global
strategy for asthma management and prevention. 2014.
2. National Asthma Council Australia. Australian asthma
handbook. Version 1. Melbourne. National Asthma
Council Australia. 2014. At: www.nationalasthma.org.au/
handbook. Accessed 4 June 2014.
3. Australian Institute of Health and Welfare. Risk factors,
diseases and death- chronic respiratory conditions. How
much is spent on asthma? At: www.aihw.gov.au/asthma-
4. Australian Centre for Asthma Monitoring. Asthma in
Australia 2011. Canberra: Australian Institute of Health
and Welfare; 2011. At: www.aihw.gov.au/publication-
5. Price D, Bosnic-Anticevich S, Briggs A, et al. Inhaler
competence in asthma: common errors, barriers to use
and recommended solutions. Respir Med. 2013 Jan;
6. Australian Institute of Health and Welfare. Vaccination
uptake among people with chronic respiratory disease.
Canberra: Australian Institute of Health and Welfare;
2012. At: www.aihw.gov.au/WorkArea/DownloadAsset.
7. Saini B, Krass I, Smith L, et al. Role of community
pharmacists in asthma – Australian research highlighting
pathways for future primary care models. Med J Aust.
8. Pharmaceutical Society of Australia. Professional practice
standards. Version 4. Canberra: Pharmaceutical Society of
Australia: 2011. At: www.psa.org.au/supporting-practice/
9. WHO Health topics. Health promotion. 2014. At: www.
10. Fathima M, Naik-Panvelkar P, et al. The role of community
pharmacists in screening and subsequent management
of chronic respiratory diseases: a systematic review. Pharm
11. Juniper EF, Bousquet J, Abetz L, et al. Identifying ‘well-
controlled’ and ‘not well-controlled’ asthma using the
asthma control questionnaire. Resp Med 2006;100:616–21.
12. LeMay KS, Armour CL, Reddel HK. Performance of a brief
asthma control screening tool in community pharmacy: a
cross-sectional and prospective longitudinal analysis. Prim
Care Respir J. 2014;23(1):79–84.
13. Fuller JM, Wong KK, Krass I, et al. Sleep disorders screening,
sleep health awareness, and patient follow-up by
community pharmacists in Australia. Patient Educ Couns.
14. Noor ZM, Smith AJ, Smith SS, et al. A study protocol: A
community pharmacy-based intervention for improving
the management of sleep disorders in the community
settings. BMC Health Serv Res. 2014;14:74.
15. Allan H, Diamandis S, Saini B, et al. A collaborative screening,
referral and management process to improve health
outcomes in chronic obstructive pulmonary disease
(COPD). Final report to the Pharmacy Guild of Australia.
16. Lung Foundation Australia. COPD pharmacy training
and support program. At: http://lungfoundation.com.
17. Immunise Australia Program. Older Australians. 2013.
PBS Information: This product is listed on the PBS as an anti-infective for ophthalmological use.
Please Review Product Information before prescribing. Full Product Information is available from Aspen Pharma upon request.
Abridged Product Information: Chlorsig® (chloramphenicol). Indications: For the treatment of bacterial conjunctivitis. Contraindications: Hypersensitivity and/or toxic reaction to the drug.
Precautions: Bone marrow hypoplasia, including aplastic anaemia and death, has been rarely reported following local application of chloramphenicol. Chloramphenicol should not be used when less
potentially dangerous agents would be expected to provide effective treatment. Ophthalmic agents may retard corneal wound healing. Eye pain/injury, severe ocular infections, contact lenses, dry eye
syndrome, glaucoma, concomitant use of other ocular medications, surgery or laser within the last 6 months. See full PI. Adverse Effects: Local irritation (itching/burning), angioneurotic oedema;
anaphylaxis, urticaria, fever, vesicular and maculopapular dermatitis, blood dyscrasias. Pregnancy Category: A. Dosage and administration: Eye Drops. Adults and children (2 years and over): Instil 1
or 2 drops in the affected eye(s) every two to six hours for up to 5 days. Eye Ointment. Adults and children (2 years and over): Apply 1.5 cm into lower eye lid of the affected eye every three hours for up to 5
days. Chlorsig is not recommended for children under 2 years except on medical advice. Presentation: Eye Drops. Store between 2-8°C until opened. Refrigerate. Do not freeze. On opening, the drops may
be stored at room temperature (below 25°C). Eye Ointment. Store below 25°C. Schedule: S3. ® Chlorsig is a registered trademark of Aspen.
References: 1. Chlorsig Product Information (Oct, 2010). 2. Rose PW 2005; 366:37-43. 3. Miller IM. 1992; 6(Pt 1):111-4. *Aspen Australia is comprised of Aspen Asia Pacific Pty Ltd (ABN 75
146 444 484) and its subsidiaries including Aspen Pharmacare Australia Pty Ltd (ABN 51 096 236 985), Aspen Pharma Pty Ltd (ABN 88 004 118 594), Aspen
Nutritionals Australia Pty Ltd (ABN 31 160 607 509), Orphan Australia Pty Ltd (ABN 11 067 189 342), Chemists’ Own Pty Ltd (ABN 45 000 585 197) and Arrow
Pharmaceuticals Pty Ltd (ABN 17 003 144 170). All sales and marketing requests to: Aspen Pharma Pty Ltd, 34-36 Chandos Street, St Leonards NSW 2065 |
Tel +61 2 8436 8300. email@example.com | www.aspenpharma.com.au Date prepared: Dec 2013. ASP397. TAPH0014/AP.
Unstick bacterial conjunctivitis with
the proven efficacy of Chlorsig.1-3
19/12/13 10:09 AM
Links Archive Australian Pharmacist September 2014 Australian Pharmacist July 2014 Navigation Previous Page Next Page